ALX Oncology Holdings 株価情報 (NASDAQ: ALXO)

最新ニュース ALX Oncology Holdings (NASDAQ:ALXO) 株価情報

ALX Oncology Holdings

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings Inc

An Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) analyst says the company will beat second-quarter earnings per share and revenue estimates with iPhone strength overshadowing any <a href="https://www.benzinga.com/markets/25/04/44656119/trump-tariffs-could-blow-up-apple-analyst-estimates-39-5-billion-impact">potential tariff concerns.</a>
The Apple Analyst: Goldman Sachs analyst Michael Ng reiterated a Buy rating on Apple and lowered the price target from $259 to $256.
The Analyst Takeaways: Ng highlights his confidence in Apple's iPhone sales and demand ahead of the company's second-quarter financial results on May 1 after market close.
Read Also: <a href="https://www.benzinga.com/tech/25/03/44366890/apple-stock-faces-pressure-from-declining-iphone-revenue-could-companys-first-foldable-smartphone-in-2026-reverse-course">Apple Stock Faces Pressure From Declining iPhone Revenue: Could Company&#8217;s First Foldable Smartphone In 2026 Reverse Course?</a>
The analyst said the key debates for Apple's earnings will be on tariffs and demand.
Ng said the reciprocal tariff exemptions on smartphones and PCs announced on April 11 should help insulate Apple from large impacts in the near-term.
The analyst estimates Apple will report iPhone revenue of $47.8 billion in the second quarter, above a consensus estimate of $45.6 billion and up 4% year-over-year.
Ng said iPhone revenue growth will come from the launch of the iPhone 16e and demand pull-forward due to tariff concerns.
The analyst also estimates that Apple's Services revenue will be up 11% year-over-year to $26.5 billion helped by items like the App Store, iCloud+, AppleCare+, Apple One and Apple Pay.
"Against the backdrop of elevated recession risks, demand drivers such as the extended replacement cycle, new product innovation, new market expansion could be balanced by weaker consumer discretionary spending and US-brand sentiment shifts," Ng said.
Ng said tariff policy and growth concerns are an "overhang for the stock." A chart from the analyst shows that Apple stock had its worst January and March of the past 10 years in 2025.
Apple has been diversifying production away from China and moving toward India and other regions. The Cupertino, California-based company still faces uncertainty on how some items will be treated in the potential trade war.
Apple could also negotiate with suppliers to lower costs or could choose to increase the price of the iPhone. Ng said Apple last increased the price on the base iPhone in 2020 with the iPhone 12.
"Sentiment could improve in the middle of the year, where focus should pivot towards new iOS and Apple Intelligence features to be released over the rest of C2025, as well as the fall launch of the iPhone 17."
Ng said Apple's installed user base, growth in services and new product innovation should offset cyclical headwinds to product revenue.
Price Action: Apple stock is up 2.3% to $204.27 on Wednesday versus a 52-week trading range of $166.21 to $260.09. Apple stock is down 16.4% year-to-date in 2025 and up 22% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44588577/apple-stock-a-buy-on-revenue-durability-visibility-analyst-highlights-china-smartphone-sales-up-in-february">Apple Stock A Buy On &#8216;Revenue Durability &amp; Visibility&#8217;: Analyst Highlights China Smartphone Sales Up In February</a></li>
</ul>
Image: Shutterstock

Analyst Color

Analyst Ratings

Tech

Trading Ideas

AAPL

Apple Stock Can Brush Off Tariff Concerns, Analyst Says Q2 Beat Coming Thanks To iPhone Demand

WIIM

MMM stock has given up its prior gain. 3M shares were trading higher after Barclays raised its price target on the stock from $160 to $164 and maintained an Overweight rating.

Government health agencies are pushing forward an <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/hhs-fda-phase-out-petroleum-based-synthetic-dyes-nations-food-supply" rel="noreferrer noopener">overhaul of food additive rules</a> to remove petroleum-based artificial dyes from products sold in the U.S.
The effort, revealed on Wednesday, falls under health secretary&nbsp;Robert F. Kennedy Jr's larger "Make America Healthy Again" plan, which seeks to boost national health by tightening dietary guidelines.
The U.S. Food and Drug Administration (FDA) and the Department of Health and Human Services introduced a roadmap outlining the shift toward plant-based food colorings across the industry.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44909706/tariff-pressures-could-reshape-restaurant-buildout-economics-says-analyst" rel="noreferrer noopener">Tariff Pressures Could Reshape Restaurant Buildout Economics, Says Analyst</a>
"For too long, some food producers have been feeding Americans petroleum-based chemicals without their knowledge or consent," said HHS Secretary Robert F. Kennedy, Jr.
"These poisonous compounds offer no nutritional benefit and pose real, measurable dangers to our children's health and development. That era is coming to an end.
As part of the plan, approvals for two synthetic dyes, Citrus Red No. 2 and Orange B, will be rescinded in the coming months.
Regulators are coordinating with manufacturers to eliminate six commonly used food colorings: FD&amp;C Red No. 40, FD&amp;C Yellow Nos. 5 and 6, FD&amp;C Green No. 3, and FD&amp;C Blue Nos. 1 and 2 by the end of next year.
The FDA also encouraged companies to retire FD&amp;C Red No. 3 ahead of the current 2027-2028 target. To support a seamless shift, the agency intends to authorize four new naturally derived color additives in the near future.
It is also speeding up the evaluation process for substitutes such as butterfly pea flower extract, Galdieria blue, gardenia blue, and calcium phosphate. In addition, updated regulatory guidelines are being developed to assist manufacturers in meeting the new requirements.
In collaboration with the National Institutes of Health (NIH), the FDA will undertake a broad research effort to assess how food dyes influence children's development and well-being.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/04/44952308/boston-scientific-raises-annual-outlook-after-strong-heart-devices-sales-in-q1-announces-cfo-transition" target="_blank" rel="noreferrer noopener">Boston Scientific Raises Annual Outlook After Strong Heart Devices Sales In Q1, Announces CFO Transition</a></li>
</ul>
Photo by Tada Images via Shutterstock

News

General

MDLZ

MNST

FDA Targets Synthetic Food Dyes In Sweeping Nutrition Overhaul

Showcasing TSMC's latest offerings for high performance computing, smartphone, automotive, and IoT applications
TSMC ((TWSE: 2330, NYSE:<a href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) today unveiled its next cutting-edge logic process technology, A14, at the Company's North America Technology Symposium. Representing a significant advancement from TSMC's industry-leading N2 process, A14 is designed to drive AI transformation forward by delivering faster computing and greater power efficiency. It is also expected to enhance smartphones by improving their on-board AI capabilities, making them even smarter. Planned to enter production in 2028, the current A14 development is progressing smoothly with yield performance ahead of schedule.
Compared with the N2 process, which is about to enter volume production later this year, A14 will offer up to 15% speed improvement at the same power, or up to 30% power reduction at the same speed, along with more than 20% increase in logic density. Leveraging the Company's experience in design-technology co-optimization for nanosheet transistor, TSMC is also evolving its TSMC NanoFlex&#x2122; standard cell architecture to NanoFlex&#x2122; Pro, enabling greater performance, power efficiency and design flexibility.

TSMC Unveils Next-Generation A14 Process At North America Technology Symposium; A14 Will Offer Up To 15% Speed Improvement At The Same Power, Or Up To 30% Power Reduction At The Same Speed, Along With More Than 20% Increase In Logic Density

Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) will be reporting its first-quarter earnings on Thursday before the market opens. Wall Street expects earnings per share of $2.14 and revenue of $15.33 billion.
The stock is down a painful 38.04% over the past year and has dropped 20.73% year-to-date. Even in the past month, it&#8217;s off by 14.85%, making it one of the more bruised names among Big Pharma peers.
Let's look at what the charts indicate for Merck stock and how it currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/04/44907790/gilead-cancer-drug-combined-with-mercks-drug-effective-in-difficult-to-treat-type-of-breast-cancer">Gilead Cancer Drug Combined With Merck&#8217;s Drug Effective In Difficult To Treat Type Of Breast Cancer</a>
<h1 class="wp-block-heading">Merck Stock Is In A Bearish Mess Ahead Of Q1 Earnings</h1>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0423"><img loading="lazy" decoding="async" width="627" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23123431/Screenshot-2025-04-23-at-10.04.18-PM.png" alt="" class="wp-image-884728" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23123431/Screenshot-2025-04-23-at-10.04.18-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23123431/Screenshot-2025-04-23-at-10.04.18-PM-300x234.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0423" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Technically, Merck stock is in a bearish mess — but not without glimmers of optimism. Merck stock is trading well below its five-, 20- and 50-day exponential moving averages, a sign the stock is in a strongly bearish trend. However, there's an undercurrent of buying pressure that could set up a bullish reversal if earnings offer any upside surprise.
At $78.56, Merck&#8217;s stock is just above its eight-day simple moving average (SMA) of $78.32 — a short-term bullish signal. But zoom out and it gets grim: the 20-day SMA sits at $82.12 and the 50-day SMA at $87.48, both pointing to technical bearish signals. 
The 200-day SMA? A daunting $102.90.
Momentum indicators also flash red: the MACD (moving average convergence/divergence) is at a negative at 3.36, and the RSI (relative strength index) is at 36.36, hovering near oversold territory. 
In short, bears still run the show — unless bulls latch onto a strong first quarter earnings.
<h1 class="wp-block-heading">Merck Analysts See 29% Upside</h1>
Ratings &amp; Consensus Estimates: Despite the technical gloom, the Street isn't giving up just yet. Merck holds a Buy consensus rating with a mean price target of $121. More recently, Cantor Fitzgerald, Guggenheim and Deutsche Bank issued fresh ratings, averaging a $101.67 target, implying a potential upside of 29.41% from current levels.
MRK Stock Price Action: Merck stock was trading at $78.68, down 0.37% at the time of publication Wednesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44895495/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Technicals

Previews

Merck Stock Slumps Ahead Of Q1 Earnings: Can Bulls Find Relief In Buying Pressure?

<a href="https://www.bloomberg.com/news/articles/2025-04-23/lions-gate-shareholders-approve-breakup-into-two-companies" title="https://www.bloomberg.com/news/articles/2025-04-23/lions-gate-shareholders-approve-breakup-into-two-companies">https://www.bloomberg.com/news/articles/2025-04-23/lions-gate-shareholders-approve-breakup-into-two-companies</a>

Lions Gate Entertainment Corporation Class A Voting Shares

LGF/A

Lions Gate Entertainment Corporation Class B Non-Voting Shares

LGF/B

'Lions Gate Shareholders Approve Breakup Into Two Companies' - Bloomberg News

Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) has rallied 23% iover the past week, gaining momentum on the back of rising whale transactions and an <a href="https://www.benzinga.com/money/pepe-price-prediction">uptick in new holders</a>.  
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>&nbsp;$0.058857</td>
<td>$3.7 billion</td>
<td>+5.3%&nbsp;</td>
<td>+23.6%&nbsp;</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1782</td>
<td>$26.6 billion</td>
<td>+4.2%&nbsp;</td>
<td>+14.8%&nbsp;</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001352</td>
<td>$8 billion</td>
<td>+3.9%&nbsp;</td>
<td>+14.4%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto analyst Davie Satoshi <a href="https://x.com/NFTdavie/status/1915026394490294418">says </a>Pepe is the current meme coin market leader, calling it a &#8220;reliable barometer&#8221; for the broader trend. 
However, he warns that the 3-day Stochastic RSI is peaking, historically signaling a cooldown or short-term pullback. 
He adds that it&#8217;s usually more bullish when the RSI is at the bottom, so traders may want to wait for momentum to reset.
CryptoPepe sees Pepe &#8220;super bullish&#8221; with target 1 at $0.000001070, target 2 at $0.000001500, target 3 at $0.000002200. Target 4 and target 5 is to overtake Shiba Inu and Dogecoin.
Meanwhile, Plazma <a href="https://x.com/Plazma0x/status/1914996004429975831">says</a> the PEPE/ETH pair is gearing up for a move toward all-time highs, citing strength in both structure and sentiment. Trader y00thereum went further, saying he's "very confident" Pepe will flip Shiba Inu soon.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If you think <a href="https://twitter.com/search?q=%24PEPE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$PEPE</a> will not flip <a href="https://twitter.com/search?q=%24SHIB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SHIB</a> you are 100% retarded. &#x1f438;&#x1f4b9; <a href="https://t.co/t3GkeUZkJG">pic.twitter.com/t3GkeUZkJG</a>
&mdash; y00thereum (@y00thereum) <a href="https://twitter.com/y00thereum/status/1914801540277129354?ref_src=twsrc%5Etfw">April 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Statistics: Plazma <a href="https://x.com/Plazma0x/status/1914748587897999577">reported </a>314 new holders joined the Pepe ecosystem on April 23, bringing the total to 424,302. 
He added that the trade war de-escalation is helping risk assets, and Pepe is leading meme coins, now ranked 28th in overall crypto market cap.
IntoTheBlock data shows Pepe's large transaction volume and daily active addressed increased by 28.7% and 29.9%, respectively, in a single day. 
Transactions greater than $100,000 spiked from 190 to 231. 
With 74% Pepe concentration by large holders, traders remain confident about the meme coin's long-term price trajectory.  
Coinglass data shows Pepe derivatives trading volume expanded by 12.6% and open interest zoomed 5.4% higher in a single day.
Read Next:&nbsp;
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44846673/meme-coin-market-is-very-much-alive-can-dogecoin-shiba-inu-fartcoin-bounce-back">Meme Coin Market Is &#8216;Very Much Alive&#8217;: Can Dogecoin, Shiba Inu, Fartcoin Bounce Back?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Pepe Surges 23% In 7 Days: Can It Flip Shiba Inu, Dogecoin?

On Tuesday, Nomura Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMR#NYSE">NMR</a>) disclosed a definitive agreement to acquire Macquarie Group, Ltd.&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MCQEF#OTC">MCQEF</a>) public asset management operations in the U.S. and Europe in an <a target="_blank" href="https://www.benzinga.com/topic/why-its-moving" rel="noreferrer noopener">all-cash deal valued at $1.8 billion</a>.
The deal includes around $180 billion in assets under management from retail <a target="_blank" href="https://www.nomuraholdings.com/news/nr/holdings/20250422/20250422.html" rel="noreferrer noopener">and</a> institutional clients, spanning equity, fixed income, and multi-asset strategies.
The transaction is expected to close by the year-end, pending regulatory approvals and customary closing conditions.
This acquisition is projected to enhance Nomura&#8217;s global reach and capabilities of its Investment Management Division, which currently oversees approximately $590 billion in assets.
Following the deal&#8217;s completion, Nomura&#8217;s total assets under management are expected to rise to roughly $770 billion, with over 35% of those assets <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">managed for clients outside Japan</a>.
The transaction will also establish the company&#8217;s substantial operational base in Philadelphia.
Kentaro Okuda, Nomura President and Group CEO, said &#8220;This acquisition will align with our 2030 global growth and diversification ambitions to invest in stable, high margin businesses,&#8221;
As of December 31, 2024, cash and cash deposits stood <a target="_blank" href="https://www.nomuraholdings.com/investor/summary/financial/data/2025_3q_pres.pdf" rel="noreferrer noopener">at </a>5.575 billion Yen.
Price Action: NMR shares are up 2.75% at $5.600&nbsp;at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/upgrades/25/04/44935871/self-storage-reits-score-upgrade-from-bofa-analyst-8-decline-in-new-construction-helps-sector" target="_blank" rel="noreferrer noopener">Self-Storage REITs Score Upgrade From BofA Analyst: 8% Decline In New Construction Helps Sector</a></li>
</ul>
Photo via Shutterstock

Equities

Large Cap

MCQEF

Nomura Eyes Global Growth With $1.8 Billion Macquarie Asset Buyout, Targets Growing AUM To $770 Billion

<a href="https://www.bloomberg.com/news/articles/2025-04-23/ubs-general-atlantic-said-to-discuss-private-credit-partnership">https://www.bloomberg.com/news/articles/2025-04-23/ubs-general-atlantic-said-to-discuss-private-credit-partnership</a>

'UBS, General Atlantic Discuss Private Credit Partnership'- Bloomberg

<a href="https://subscriber.politicopro.com/article/2025/04/natural-resources-plans-may-6-reconciliation-markup-00306251" title="https://subscriber.politicopro.com/article/2025/04/natural-resources-plans-may-6-reconciliation-markup-00306251">https://subscriber.politicopro.com/article/2025/04/natural-resources-plans-may-6-reconciliation-markup-00306251</a>

Macro Economic Events

Politics

Economics

AREC

Market Vectors Rare Earth/Strategic Metals Etf

REMX

UAMY

Politico Reporter Joshua Siegel Posts On X "Scooplet: House Natural Resources Committee plans May 6 reconciliation markup. Their portion of GOP mega bill is expected to expand oil and gas lease sales and boost development of new mines for critical minerals"

BABA

BIDU

FUTU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

TCOM

XPEV

Shares of US-listed Chinese companies are trading higher after President Trump indicated the final tariff rate with China would be "substantially" below than the current 145% but not 0%.

<a href="https://www.axios.com/2025/04/23/musk-bessent-trump-white-house-irs" title="https://www.axios.com/2025/04/23/musk-bessent-trump-white-house-irs">https://www.axios.com/2025/04/23/musk-bessent-trump-white-house-irs</a>

TSLA

'Scoop: Musk vs. Bessent Dispute Erupted Into West Wing Shouting Match' - Axios

<a href="https://www.scmp.com/news/china/diplomacy/article/3307667/european-parliament-final-stages-talks-china-remove-sanctions?module=top_story&amp;pgtype=homepage">https://www.scmp.com/news/china/diplomacy/article/3307667/european-parliament-final-stages-talks-china-remove-sanctions?module=top_story&amp;pgtype=homepage</a>

'European Parliament In 'Final Stages' Of Talks With China To Remove Sanctions'- South China Morning Post

Skechers USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) is preparing to release its quarterly earnings on Thursday, 2025-04-24. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Skechers USA to report an earnings per share (EPS) of $1.17.
Skechers USA bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
The company's EPS missed by $0.10 in the last quarter, leading to a 12.68% drop in the share price on the following day.
Here's a look at Skechers USA's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.75</td>
<td>1.15</td>
<td>0.95</td>
<td>1.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.65</td>
<td>1.26</td>
<td>0.91</td>
<td>1.33</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-13.0%</td>
<td>-4.0%</td>
<td>2.0%</td>
<td>11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745431394_0.png" alt="eps graph" />
<h3>Market Performance of Skechers USA's Stock</h3>
Shares of Skechers USA were trading at $48.03 as of April 22. Over the last 52-week period, shares are down 16.13%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analysts' Perspectives on Skechers USA</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Skechers USA.
Analysts have given Skechers USA a total of 9 ratings, with the consensus rating being Buy. The average one-year price target is $73.67, indicating a potential 53.38% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Birkenstock Holding, Crocs and Steven Madden, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Birkenstock Holding, with an average 1-year price target of $66.4, suggesting a potential 38.25% upside.</li>
<li>Analysts currently favor an Buy trajectory for Crocs, with an average 1-year price target of $130.8, suggesting a potential 172.33% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Steven Madden, with an average 1-year price target of $36.5, suggesting a potential 24.01% downside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
Within the peer analysis summary, vital metrics for Birkenstock Holding, Crocs and Steven Madden are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skechers USA</td>
<td>Buy</td>
<td>12.82%</td>
<td>$1.18B</td>
<td>2.30%</td>
</tr>
<tr>
<td>Birkenstock Holding</td>
<td>Outperform</td>
<td>19.41%</td>
<td>$218.03M</td>
<td>0.75%</td>
</tr>
<tr>
<td>Crocs</td>
<td>Buy</td>
<td>3.09%</td>
<td>$572.93M</td>
<td>20.72%</td>
</tr>
<tr>
<td>Steven Madden</td>
<td>Neutral</td>
<td>12.05%</td>
<td>$235.44M</td>
<td>4.14%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Skechers USA ranks highest in Gross Profit among its peers. It is in the middle for Revenue Growth and Return on Equity.
<h3>Delving into Skechers USA's Background</h3>
Skechers USA Inc is a lifestyle footwear company under the Skechers GO brand name. Products offered include various styles of women's shoes, men's shoes, girl's shoes, boy's shoes, performance shoes, and work shoes. Allied products offered are apparel, bags, eyewear, toys, and more. Its products are available for sale at department and specialty stores, athletic and independent retailers, boutiques, and internet retailers. The company's operating segments includes Wholesale and Direct-to-Consumer. It generates maximum revenue from the Wholesale segment.
<h3>Unraveling the Financial Story of Skechers USA</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Skechers USA's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 12.82%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 4.49%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Skechers USA's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.3%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Skechers USA's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.16%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Skechers USA's debt-to-equity ratio is below the industry average at 0.45, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/SKX/earnings">To track all earnings releases for Skechers USA visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Skechers USA's Earnings: A Preview

<a href="https://www.federalreserve.gov/monetarypolicy/beigebook202504-summary.htm" title="https://www.federalreserve.gov/monetarypolicy/beigebook202504-summary.htm">https://www.federalreserve.gov/monetarypolicy/beigebook202504-summary.htm</a>

Federal Reserve

Fed Beige Book: The Outlook In Several Districts Worsened Consid- Erably As Economic Uncertainty, Particularly Surrounding Tariffs, Rose; Prices Increased Across Districts, With Six Characterizing Price Growth As Modest And Six Characterizing It As Moderate, Similar To The Previous Report

Associated Banc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASB#NYSE">ASB</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-04-24. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Associated Banc will report an earnings per share (EPS) of $0.57.
The market awaits Associated Banc's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.04, leading to a 0.83% drop in the share price on the subsequent day.
Here's a look at Associated Banc's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.53</td>
<td>0.50</td>
<td>0.52</td>
<td>0.49</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.57</td>
<td>0.56</td>
<td>0.52</td>
<td>0.52</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>0.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745431385_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Associated Banc were trading at $20.88 as of April 22. Over the last 52-week period, shares are down 0.28%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ASB/earnings">To track all earnings releases for Associated Banc visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look at Associated Banc's Upcoming Earnings Report

Fed Beige Book: This Report Was Prepared At The Federal Reserve Bank Of Atlanta Based On Information Collected On Or Before April 14, 2025; Economic Activity Was Little Changed Since The Previous Report, But Uncertainty Around International Trade Policy Was Pervasive Across Reports

Federated Hermes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHI#NYSE">FHI</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-04-24. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Federated Hermes will report an earnings per share (EPS) of $0.95.
The announcement from Federated Hermes is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.07, leading to a 0.05% increase in the share price on the subsequent day.
Here's a look at Federated Hermes's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.97</td>
<td>0.92</td>
<td>0.89</td>
<td>0.88</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.04</td>
<td>1.06</td>
<td>0.96</td>
<td>0.89</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>0.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745431369_0.png" alt="eps graph" />
<h3>Tracking Federated Hermes's Stock Performance</h3>
Shares of Federated Hermes were trading at $37.23 as of April 22. Over the last 52-week period, shares are up 10.45%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analysts' Perspectives on Federated Hermes</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Federated Hermes.
With 4 analyst ratings, Federated Hermes has a consensus rating of Neutral. The average one-year price target is $39.5, indicating a potential 6.1% upside.
<h3>Comparing Ratings with Competitors</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Artisan Partners Asset and Victory Capital Holdings, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Artisan Partners Asset, with an average 1-year price target of $39.67, suggesting a potential 6.55% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Victory Capital Holdings, with an average 1-year price target of $74.4, suggesting a potential 99.84% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
Within the peer analysis summary, vital metrics for Artisan Partners Asset and Victory Capital Holdings are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Federated Hermes</td>
<td>Neutral</td>
<td>8.48%</td>
<td>$287.52M</td>
<td>7.44%</td>
</tr>
<tr>
<td>Artisan Partners Asset</td>
<td>Neutral</td>
<td>19.30%</td>
<td>$148.63M</td>
<td>16.68%</td>
</tr>
<tr>
<td>Victory Capital Holdings</td>
<td>Neutral</td>
<td>12.91%</td>
<td>$45.78M</td>
<td>6.70%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Federated Hermes ranks highest in Gross Profit among its peers. It is in the middle for Revenue Growth and Return on Equity.
<h3>Discovering Federated Hermes: A Closer Look</h3>
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $800 billion in managed assets at the end of September 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (74%) funds. The firm's cash-management operations are expected to generate around 51% of Federated's revenue this year, compared with 29%, 12%, and 7%, respectively, for the equity, fixed-income, and alternatives/multi-asset operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (65% of AUM), institutional investors (26%), and international clients (9%).
<h3>Financial Milestones: Federated Hermes's Journey</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Federated Hermes's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 8.48%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 19.09%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.44%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Federated Hermes's ROA excels beyond industry benchmarks, reaching 3.93%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.42, Federated Hermes adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/FHI/earnings">To track all earnings releases for Federated Hermes visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Uncovering Potential: Federated Hermes's Earnings Preview

Hasbro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-04-24. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Hasbro will report an earnings per share (EPS) of $0.69.
Investors in Hasbro are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.11, leading to a 2.17% drop in the share price the following trading session.
Here's a look at Hasbro's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.35</td>
<td>1.28</td>
<td>0.78</td>
<td>0.27</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.46</td>
<td>1.73</td>
<td>1.22</td>
<td>0.61</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>0.0%</td>
<td>4.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745431347_0.png" alt="eps graph" />
<h3>Hasbro Share Price Analysis</h3>
Shares of Hasbro were trading at $52.1 as of April 22. Over the last 52-week period, shares are down 18.53%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Views on Hasbro</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Hasbro.
The consensus rating for Hasbro is Buy, based on 3 analyst ratings. With an average one-year price target of $80.33, there's a potential 54.18% upside.
<h3>Comparing Ratings with Competitors</h3>
The below comparison of the analyst ratings and average 1-year price targets of Mattel, Acushnet Holdings and Brunswick, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Mattel, with an average 1-year price target of $27.0, suggesting a potential 48.18% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Acushnet Holdings, with an average 1-year price target of $71.0, suggesting a potential 36.28% upside.</li>
<li>Analysts currently favor an Buy trajectory for Brunswick, with an average 1-year price target of $73.5, suggesting a potential 41.07% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary presents essential metrics for Mattel, Acushnet Holdings and Brunswick, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hasbro</td>
<td>Buy</td>
<td>-14.53%</td>
<td>$662.90M</td>
<td>-2.81%</td>
</tr>
<tr>
<td>Mattel</td>
<td>Buy</td>
<td>1.59%</td>
<td>$835.47M</td>
<td>6.16%</td>
</tr>
<tr>
<td>Acushnet Holdings</td>
<td>Outperform</td>
<td>7.80%</td>
<td>$100.66M</td>
<td>-0.14%</td>
</tr>
<tr>
<td>Brunswick</td>
<td>Buy</td>
<td>-15.20%</td>
<td>$253.20M</td>
<td>-4.20%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Hasbro ranks at the bottom for Revenue Growth and Gross Profit, indicating lower performance in these areas compared to its peers. However, it ranks in the middle for Return on Equity, suggesting a moderate level of profitability relative to others.
<h3>Delving into Hasbro's Background</h3>
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. The firm acquired EOne in 2019, bolting on popular family properties like Peppa Pig and PJ Masks, and since has pruned noncore lines from the tie-up. Furthermore, the addition of Dungeons &amp; Dragons Beyond in 2022, offers the firm access to 19 million digital tabletop players.
<h3>Key Indicators: Hasbro's Financial Health</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Decline in Revenue: Over the 3 months period, Hasbro faced challenges, resulting in a decline of approximately -14.53% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Hasbro's net margin is impressive, surpassing industry averages. With a net margin of -3.11%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Hasbro's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.81%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Hasbro's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.51%, the company showcases efficient use of assets and strong financial health.
Debt Management: Hasbro's debt-to-equity ratio stands notably higher than the industry average, reaching 2.95. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<a href="https://www.benzinga.com/quote/HAS/earnings">To track all earnings releases for Hasbro visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Uncovering Potential: Hasbro's Earnings Preview

American Airlines Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-04-24. Here's a quick overview of what investors should know before the release.
Analysts are estimating that American Airlines Group will report an earnings per share (EPS) of $-0.63.
Investors in American Airlines Group are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.20, which was followed by a 0.41% drop in the share price the next day.
Here's a look at American Airlines Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.66</td>
<td>0.15</td>
<td>1.05</td>
<td>-0.29</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.86</td>
<td>0.30</td>
<td>1.09</td>
<td>-0.34</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>3.0%</td>
<td>0.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745431335_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of American Airlines Group were trading at $9.31 as of April 22. Over the last 52-week period, shares are down 33.12%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/AAL/earnings">To track all earnings releases for American Airlines Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of American Airlines Group's Earnings

Management

Press Releases

ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

Small Cap

Opinion

Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in  Patients with HER2-Positive Gastric Cancer

Comments

ALX Oncology Holdings

ニュース

最新ニュース ALX Oncology Holdings (NASDAQ:ALXO) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル